Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

A clinical trial is evaluating whether combining a cognitive rehabilitation program with a virtual reality (VR)-based aerobic exercise regimen will improve learning and memory in people with ...

Investing.com -- Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales projections, particularly for its Life Science and ...

The National Multiple Sclerosis Society is awarding a total of $4.6 million in funding to advance research into how the protective myelin sheath that’s damaged in multiple sclerosis (MS) can be ...

Blair’s MS is currently in remission. She exclusively told Us Weekly in August that she’s had “amazing” results with the medication Mavenclad. “It helped my movement and speech so much ...

The second deal is with German pharma company Merck for its multiple sclerosis drug Mavenclad (cladribine), and involves a new outcomes-based pricing agreement. Simon Stevens hailed the Merck ...